REPL News and Press, Replimune Group Inc. From 12/05/23

2023-12-05 12:36:51 ET More on Mid-day movers stocks. Meiwu technology company limited received nasdaq delisting determination Seeking Alpha’s Quant Rating on NuZee, Inc. Historical earnings data for NuZee, Inc. Financial information for NuZee, Inc. ...

2023-12-05 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Travere Therap...

2023-12-05 08:28:55 ET Losers: Replimune Group ( REPL ) -50% presents new data from IGNYTE clinical trial of RP1 in Anti-PD1 failed Melanoma and non-Melanoma skin cancers. iBio ( IBIO ) -38% announces pricing of $4.5 Million public offering . Designer B...

2023-12-05 08:17:14 ET More on Replimune Group Replimune: Skepticism Is Priced In Ahead Of Long-Awaited CERPASS Data (Rating Upgrade) Seeking Alpha’s Quant Rating on Replimune Group Historical earnings data for Replimune Group Financial information for...

RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in ...

2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...

WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in ...

2023-11-07 08:22:39 ET More on Replimune Group Replimune: Skepticism Is Priced In Ahead Of Long-Awaited CERPASS Data (Rating Upgrade) Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch Seeking Alpha’s Quant Rating on Replimune Group Histor...

The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinoma An initial data snapshot for all 14...

2023-11-05 10:05:05 ET Summary Replimune's fiscal health and clinical progress are being closely watched, with upcoming combination data for its lead candidate RP1 seen as a critical juncture. The company's Q2 earnings showed increased expenditures and a widening net loss, raising...